ReviewWorld journal of gastrointestinal oncology2022
Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review.
Review in World journal of gastrointestinal oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Establishment of extrahepatic bile duct cancer organoids using suspension culture and their application in clinical drug screening.Oncology letters · 2026Article
- Spectrum of Biliary and Nonbiliary Neoplasms Growing and Spreading Within the Lumen of the Bile Ducts.Cancers · 2026Review
- CBC3T-3: a novel patient-derived cisplatin-resistant distal cholangiocarcinoma cell line harboring multiple TP53 missense mutations.Human cell · 2026Article
- Article
- Contrast-enhanced ultrasound for diagnosing subtypes of intrahepatic cholangiocarcinoma: a comparative study with poorly differentiated hepatocellular carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Establishment and characterization of a new Chinese extrahepatic cholangiocarcinoma cell line, EBC-X1.Human cell · 2025Article
- Clinical value and applicability of radiomics in differential diagnosis of dual-phenotype hepatocellular carcinoma and intrahepatic cholangiocarcinoma.World journal of radiology · 2025Article
- Apoptosis-Inducing and Proliferation-Inhibiting Effects of Doramectin on Mz-ChA-1 Human Cholangiocarcinoma Cells.International journal of molecular sciences · 2024Article
- Article
- Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2024Article
- National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma.World journal of gastroenterology · 2024Review
- Comprehensive Immunogenomic Profiling ofJCO precision oncology · 2024Article
- Assessment of safety and adverse events in endoscopic radiofrequency ablation for malignant biliary obstruction.Therapeutic advances in gastroenterology · 2024Article
- Cholangiocarcinoma in early childhood.Autopsy & case reports · 2024Article
- Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman withExploration of targeted anti-tumor therapy · 2024Article
- Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version).Journal of clinical and translational hepatology · 2023Article
- High-grade dysplasia of the cystic duct margin: how should this be managed?BMJ case reports · 2023Article
- Diagnosis of IndolentFederal practitioner : for the health care professionals of the VA, DoD, and PHS · 2023Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinomas are a heterogeneous group of highly aggressive cancers that may arise anywhere within the biliary tree. There is a wide geographical variation with regards to its incidence, and risk-factor associations which may include liver fluke infection, primary sclerosing cholangitis, and hepatolithiasis amongst others. These tumours are classified into intrahepatic, perihilar and distal based on their anatomical location. Morphologically, intrahepatic cholangiocarcinomas are further sub-classified into small and large duct variants. Perihilar and distal cholangiocarcinomas are usually mucin-producing tubular adenocarcinomas. Cholangiocarcinomas develop through a multistep carcinogenesis and are preceded by dysplastic and in situ lesions. While clinical characteristics and management of these tumours have been extensively elucidated in literature, their ultra-structure and tumour biology remain relatively unknown. This review focuses on the current knowledge of pathological characteristics, molecular alterations of cholangiocarcinoma, and its precursor lesions (including biliary intraepithelial neoplasia, intraductal papillary neoplasms of the bile duct, intraductal tubulopapillary neoplasms and mucinous cystic neoplasm).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.